Benitec Biopharma Inc. Common Stock
BNTCStock
$12.66−2.04%52W
Market Cap$445.75M
P/E—
Div yield—
Beta0.27
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-0.42%
Price vs S&P 500 (4W)14.96%
VGM Score34.53
Market Capitalization$445.75M
Earnings Surprise History
Q3 26-0.24est. -0.28
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.38
4.38
4.31
4.25
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BNTCBenitec Biopharma Inc. Common Stock | F | — | C | $12.66 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Benitec Biopharma is a clinical-stage biotechnology company developing novel genetic medicines designed to provide one-time curative treatments. The company's lead program, BB-301, is a silence-and-replace therapeutic targeting Oculopharyngeal Muscular Dystrophy (OPMD), a rare, chronic genetic disorder with no currently effective treatments.